Characteristics and Clinical Outcomes of Non-small Cell Lung Cancer Patients in Korea With MET Exon 14 Skipping
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hur, Joon Young | - |
dc.contributor.author | Ku, Bo Mi | - |
dc.contributor.author | Shim, Joon Ho | - |
dc.contributor.author | Jung, Hyun Ae | - |
dc.contributor.author | Sun, Jong-Mu | - |
dc.contributor.author | Lee, Se-Hoon | - |
dc.contributor.author | Ahn, Jin Seok | - |
dc.contributor.author | Park, Keunchil | - |
dc.contributor.author | Ahn, Myung-Ju | - |
dc.date.accessioned | 2023-09-18T06:39:41Z | - |
dc.date.available | 2023-09-18T06:39:41Z | - |
dc.date.created | 2023-07-19 | - |
dc.date.issued | 2020-05 | - |
dc.identifier.issn | 0258-851X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/190697 | - |
dc.description.abstract | Background/Aim: MET exon 14 skipping occurs in 3-4% of patients with lung adenocarcinomas. In this study, we performed a comprehensive analysis of clinical data from Korean non-small cell lung cancer (NSCLC) patients with MET exon 14 skipping. Patients and Methods: Overall, 1,020 patients diagnosed with NSCLC between January 2015 and July 2017 were analyzed by next-generation sequencing. Results: MET exon 14 skipping was identified in 20 NSCLC patients (1.9%). The median age was 69 years (range=39-86 years), 60.0% were male, and most (55.0%) were ever-smokers. For first-line chemotherapy, the median overall survival was 9.5 months and progression free survival was 4.0 months, respectively. Twelve patients received pemetrexed-based chemotherapy and the overall response rate was 33.3% (4/12). Among four crizotinib-treated patients, one continued therapy for 8 months with the best response being disease stability. Conclusion: Given the poor clinical outcome and response to therapy for NSCLC, and the availability of promising anti-tumor MET inhibitors, screening for the MET exon 14 skip mutation should be incorporated into clinical practice. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | INT INST ANTICANCER RESEARCH | - |
dc.title | Characteristics and Clinical Outcomes of Non-small Cell Lung Cancer Patients in Korea With MET Exon 14 Skipping | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Hur, Joon Young | - |
dc.identifier.doi | 10.21873/invivo.11920 | - |
dc.identifier.scopusid | 2-s2.0-85084898801 | - |
dc.identifier.wosid | 000530682800058 | - |
dc.identifier.bibliographicCitation | IN VIVO, v.34, no.3, pp.1399 - 1406 | - |
dc.relation.isPartOf | IN VIVO | - |
dc.citation.title | IN VIVO | - |
dc.citation.volume | 34 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 1399 | - |
dc.citation.endPage | 1406 | - |
dc.type.rims | ART | - |
dc.type.docType | 정기학술지(Article(Perspective Article포함)) | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Research & Experimental Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
dc.subject.keywordAuthor | Crizotinib | - |
dc.subject.keywordAuthor | MET Exon 14 Skipping | - |
dc.subject.keywordAuthor | NSCLC | - |
dc.identifier.url | https://iv.iiarjournals.org/content/34/3/1399 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.